ALSN News (online only)

MDA has joined forces with the ALS Association to fight ALS through a grant to James Shorter at the University of Pennsylvania

Posted on Wednesday, December 3, 2014 - 14:09, By: Margaret Wahl
MDA has joined forces with the ALS Association (ALSA) to fund a new research project aimed at finding a potential therapy for amyotrophic lateral sclerosis (ALS). The two organizations have made a $240,000 award to molecular biologist James Shorter at the Perelman School of Medicine at the University of Pennsylvania. Shorter also has an existing MDA grant for related research.

In a phase 2 trial, the drug mexiletine was found to reduce the frequency of muscle cramps but not to affect motor or respiratory function

Posted on Tuesday, November 25, 2014 - 15:55, By: Margaret Wahl
Preliminary results of a trial of mexiletine in 60 people with amyotrophic lateral sclerosis (ALS) show the drug is reasonably safe and well tolerated and possibly effective for reducing the frequency and intensity of muscle cramps associated with this disorder. However, no benefits were seen in mexiletine recipients versus placebo recipients on tests of motor or respiratory function.

Israeli biotechnology company BrainStorm will test its adult stem cells, derived from bone marrow, in 48 ALS patients at three sites

Posted on Friday, June 13, 2014 - 10:06, By: Margaret Wahl
Israeli biotechnology company BrainStorm Cell Therapeutics has enrolled the first participant in a phase 2, U.S.-based trial of adult stem cell transplantation to treat amyotrophic lateral sclerosis (ALS).

Results of a large-scale trial of tirasemtiv in ALS show the drug may slow respiratory decline without improving scores on the ALS Functional Rating Scale

Posted on Thursday, May 1, 2014 - 14:07, By: Margaret Wahl
The experimental drug tirasemtiv, in development by South San Francisco biopharmaceutical company Cyokinetics as a potential treatment for amyotrophic lateral sclerosis (ALS), slowed the decline in at least one measure of respiratory function in a recent, large-scale study known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS).

An MDA-supported research team has found that expansions of the C9ORF72 gene cause formation of abnormally shaped DNA and RNA, with adverse effects on cells

Posted on Wednesday, April 23, 2014 - 15:11, By: Margaret Wahl
Jiou Wang, an MDA research grantee at Johns Hopkins University, says the new findings could have implications for several disorders.

Findings show TDP43 protein transports RNA molecules in motor neurons; impairment of the function may help drive the amyotrophic lateral sclerosis disease process

Posted on Wednesday, March 12, 2014 - 14:28, By: Amy Madsen
TDP43 protein is involved in the transport of vital cargo within motor neurons, the muscle-controlling nerve cells that are lost in amyotrophic lateral sclerosis (ALS), a multinational research team reports. Further, disruption of the function results from ALS-causing mutations in the gene for the TDP43 protein and may contribute to the ALS disease process.